DeepMed Research

Xiamen Amoytop Biotech Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

Phase 3

Completed

Conditions: Non-Myeloid Malignancy

Interventions: Drug: YPEG-rhG-CSF
Drug: rhG-CSF/PEG-rhG-CSF

First Posted Date: 2020-07-10

Last Posted Date: 2022-02-09

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 398

Registration Number: NCT04466137

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Completed

Conditions: Hepatitis B

Interventions: Drug: Peginterferon Alfa-2B
Drug: Peginterferon Alfa-2A

First Posted Date: 2017-06-08

Last Posted Date: 2021-04-13

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 473

Registration Number: NCT03181113

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Second Affiliated Hospital Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳
Southwest Hospital, Chongqing, Chongqing, China

and more 25 locations

A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Ypeginterferon alfa-2b
Drug: Granulocyte-macrophage colony stimulating factor

First Posted Date: 2015-01-06

Last Posted Date: 2017-01-25

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 110

Registration Number: NCT02332473

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China
🇨🇳
Tongji Hospital, Huazhong University of Science & Technology, Wuhan, Hubei, China

and more 9 locations

Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

Phase 2

Completed

Conditions: Breast Cancer
Non Small Cell Lung Cancer

Interventions: Drug: PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Drug: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Drug: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Drug: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

First Posted Date: 2013-12-09

Last Posted Date: 2018-07-17

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT02005458

Locations: 🇨🇳
Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, Fujian, China
🇨🇳
Shanghai Changzheng Hospital, Shanghai, China
🇨🇳
Shaaxi Provincial Tumor Hospital, Xi'an, Shaanxi, China

and more 9 locations

PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pegylated rhEPO
Drug: EPIAO®

First Posted Date: 2013-02-27

Last Posted Date: 2015-08-31

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT01800305

Locations: 🇨🇳
302 Military Hospital of China, Beijing, China

Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Phase 3

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Ypeginterferon alfa-2b
Drug: Pegasys

First Posted Date: 2013-01-03

Last Posted Date: 2015-08-31

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 820

Registration Number: NCT01760122

Locations: 🇨🇳
Beijing Youan Hospital, Capital Medical University, Beijing, China
🇨🇳
Xiangya Hospital, Central-south University, Changsha, China
🇨🇳
Xiangya Second Hospital, Central-south University, Changsha, China

and more 40 locations

Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

Phase 3

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ypeginterferon alfa-2b
Drug: Pegasys

First Posted Date: 2012-04-20

Last Posted Date: 2014-10-07

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 770

Registration Number: NCT01581398

Locations: 🇨🇳
85 Militay Hospital, Shanghai, China
🇨🇳
Huashan Hospital, Shanghai, China
🇨🇳
Xiangya Hospital, Central-south University, Changsha, China

and more 39 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Peginterferon alfa
Drug: Peginterferon alfa 2a
Drug: Peginterferon alfa-2a

First Posted Date: 2011-04-27

Last Posted Date: 2012-01-31

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 39

Registration Number: NCT01343186

Locations: 🇨🇳
302 Military Hospital of China, Beijing, China

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pegylated-Somatropin
Drug: YPEG-Somatropin

First Posted Date: 2011-04-20

Last Posted Date: 2013-02-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT01339182

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients

Phase 1

Completed

Conditions: Chemotherapy Patients

Interventions: Drug: YPEG-Filgrastim

First Posted Date: 2010-11-10

Last Posted Date: 2013-02-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT01238562

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy